Location History:
- Palo Alto, CA (US) (1998 - 2002)
- Seattle, WA (US) (2002 - 2023)
Company Filing History:
Years Active: 1998-2023
Title: Mark Andrew Troll: Innovator in Nanopore Technology
Introduction
Mark Andrew Troll, based in Seattle, WA, has made significant contributions to the field of nanopore technology. With 25 patents to his name, he has established himself as a prominent inventor and researcher. His latest innovations focus on Mycobacterium smegmatis porin nanopores, showcasing his commitment to advancing scientific knowledge through practical applications.
Latest Patents
Troll's most recent patents include methods and systems involving MSP nanopores. These innovations primarily consist of porin nanopores, which may encompass wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, as well as their mutant counterparts and single-chain Msp porins. Additionally, these patents detail bacterial strains capable of inducible Msp porin expression, highlighting the versatility and potential applications of his work in various scientific fields.
Career Highlights
Throughout his career, Mark Andrew Troll has worked with renowned organizations such as Agilent Technologies, Inc., and the University of Washington. His experiences in these institutions have allowed him to hone his expertise and collaborate on groundbreaking research projects, further solidifying his reputation as an influential inventor.
Collaborations
Troll has collaborated with notable figures in the scientific community, including Jens H. Gundlach and Michael Niederweis. These partnerships have enriched his research and contributed to the successful development of innovative technologies in the realm of nanopores.
Conclusion
Mark Andrew Troll continues to push the boundaries of nanopore technology with his inventive spirit and dedication to research. His impressive portfolio of patents reflects his commitment to innovation and highlights his impact on the scientific landscape. As he advances his work, the innovations stemming from his expertise hold promise for a wide range of applications in biotechnology and beyond.